Phase II trial of clarithromycin/clofazimine/rifabutin [RHB 104] in patients with Crohn's disease secondary to Mycobacterium avium paratuberculosis infection

Trial Profile

Phase II trial of clarithromycin/clofazimine/rifabutin [RHB 104] in patients with Crohn's disease secondary to Mycobacterium avium paratuberculosis infection

Not stated
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2013

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Crohn's disease; Mycobacterium avium paratuberculosis infections
  • Focus Therapeutic Use
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 16 Sep 2013 Status changed from planning to unconfirmed (trial never initiated).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top